Research Reference Only: All content on this page describes delivery methods and bioavailability data as documented in published preclinical research involving animal models and in vitro systems. This content is for research reference only and does not constitute guidance for human use or experimentation of any kind.
Intravenous Administration in Animal Research Models
Published preclinical literature documents intravenous peptide delivery in rodent IV infusion models and murine subjects for rapid systemic distribution studies of NAD-plus, Epithalon, and MOTS-C.
Research Overview
Intravenous administration in animal research models provides immediate systemic peptide distribution and is used in preclinical research where rapid plasma concentration achievement or precise pharmacokinetic characterization is required. NAD-plus IV infusion has been studied in rodent subjects to characterize tissue NAD-plus restoration kinetics and compare IV-mediated CNS NAD-plus delivery against intranasal and oral routes. Epithalon IV administration in murine aging models has been documented in the Khavinson laboratory series, with systemic delivery used to examine telomerase activity and immune parameter responses in aged mouse cohorts. MOTS-C intravenous delivery in murine subjects has been applied to study pharmacokinetic distribution and downstream AMPK activation in metabolic target tissues including skeletal muscle and adipose tissue.
IV administration in rodent models requires tail vein or jugular vein cannulation, with published protocols specifying maximum injection rates and volumes to minimize hemodynamic stress in research subjects. NAD-plus IV infusion research in rodent subjects has documented rapid plasma clearance with tissue-specific NAD-plus uptake kinetics that differ substantially from oral or subcutaneous precursor supplementation routes, providing distinct pharmacokinetic data for research design.
Preclinical Bioavailability Data
Data from Published Preclinical Literature Only| Model | Compound | Finding | Source |
|---|---|---|---|
| Sprague-Dawley rat IV infusion model | NAD+ | Intravenous NAD-plus delivery in Sprague-Dawley rat models documented rapid plasma distribution with measurable tissue NAD-plus elevation in liver and skeletal muscle within 15 to 30 minutes of infusion completion, with brain tissue NAD-plus restoration documented at longer post-infusion intervals in published neurological recovery studies. | Neuronal NAD depletion and intravenous repletion research literature |
| C57BL/6 aging mouse model | Epithalon | In Khavinson laboratory C57BL/6 aging mouse cohort studies, intravenous Epithalon delivery was employed alongside subcutaneous routes, with systemic administration documented to produce equivalent telomerase activity changes in peripheral blood mononuclear cells compared to subcutaneous delivery in age-matched study subjects. | Khavinson et al., Institute of Bioregulation and Gerontology aging series |
| Murine metabolic model | MOTS-C | In murine metabolic research, intravenous MOTS-C delivery was used to characterize the pharmacokinetic distribution and skeletal muscle AMPK activation kinetics of this mitochondrial-derived peptide, with documented GLUT4 translocation in skeletal muscle tissue within 60 minutes of IV administration in high-fat diet mouse subjects. | Lee et al. and MOTS-C metabolic research literature, 2015 to present |
| Sprague-Dawley rat CNS ischemia model | NAD+ | Published MCAO ischemia studies in Sprague-Dawley rats have employed IV NAD-plus delivery immediately following ischemic insult to characterize neuroprotective potential, with treated animals showing reduced infarct volume and improved neurological deficit scores relative to saline-infused ischemia controls. | Neuroprotective NAD repletion preclinical literature, multiple published studies |
All data above describes findings from published preclinical animal model and in vitro research only. No human bioavailability data is presented or implied.
Stability and Handling in Research
NAD-plus stability in IV-compatible aqueous formulations has been characterized at pH 6.5 to 7.5 with documented degradation accelerated above 37 degrees Celsius and in alkaline conditions. Published IV formulation studies document sterile filtration through 0.22 micron membranes as standard for IV-route preparations in animal research, with NAD-plus solutions prepared fresh immediately before administration due to documented instability during extended storage at room temperature. MOTS-C and Epithalon IV formulation stability in sterile saline has been characterized at 4 degrees Celsius with documented structural integrity maintenance over 24-hour preparation-to-use windows in published rodent study protocols.
All stability information above is derived from in vitro assay data and published analytical chemistry literature. This information describes laboratory characterization findings only.
Research Design Considerations
- 1
IV access and cannulation: Published rodent IV delivery protocols require tail vein or surgically implanted jugular cannula access, with published guidelines specifying maximum injection rates of 0.5 to 1.0 mL per minute in murine subjects to avoid hemodynamic stress.
- 2
Sterile preparation requirements: IV-route peptide delivery in animal research requires sterile filtration and pyrogen-free formulation conditions, with documented microbial contamination representing the primary acute safety concern in IV rodent research models.
- 3
Pharmacokinetic sampling: IV administration provides the most complete pharmacokinetic data set because 100% systemic bioavailability allows precise calculation of volume of distribution and elimination half-life, which are not calculable from extravascular routes alone.
- 4
Comparison to subcutaneous controls: Published rodent studies often include parallel subcutaneous administration groups to characterize bioavailability relative to the IV gold standard and calculate extravascular bioavailability fractions for specific compounds.
Compounds Studied Via This Method
These compounds have been examined using this delivery method in published preclinical and in vitro research.
Frequently Asked Questions
Continue Your Research
Explore the full Research Library for compound comparisons, use cases, and study indexes. All compounds available at minimum 98% HPLC-verified purity for in vitro research use only.
All compounds are strictly for in vitro research use only and not intended for human consumption.